Reshma Kewalramani - Apr 27, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 27, 2023
Transactions value $
-$1,124,726
Form type
4
Date filed
5/1/2023, 04:26 PM
Previous filing
Feb 28, 2023
Next filing
Jun 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$546K -1.61K -1.24% $338.69 128K Apr 27, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$566K -1.67K -1.3% $339.43 127K Apr 27, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$12.9K -38 -0.03% $340.19 127K Apr 27, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022.
F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99).
F4 Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98).